Post-earnings recap
Reported
Mon, Nov 9, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kodiak Sciences reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 4.22%, likely due to positive sentiment around their ongoing projects and future potential. Investors may be optimistic about the company's pipeline despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.80 | N/A | -20.12% |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their pipeline despite the EPS miss. They emphasized the potential of their key projects.
Management expressed confidence in their ongoing projects and research.
They highlighted the importance of upcoming clinical trials.